Clinical Trials in Philadelphia

Showing 10961-10980 of 17,926 trials

Testing the Influence of Different Sugary Drink Warning Label Designs

NCT03648138

The aim of this study is to compare different sugary drink labels to see which most influence knowledge, beliefs, purchase intentions and choices. Parents of children ages 6-11 will shop in a virtual convenience store after being randomized to 1 of 4 conditions: 1) calorie labels; 2) text warning labels; 3) graphic sugar warning labels; or 4) graphic health warning. This study will provide data comparing the influence of sugary drink text warning labels and two kinds of graphic warning labels.

ObesityWeight GainDiabetes Type 2

University of Pennsylvania1,016 participantsStarted Jan 2020

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02315430

This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse. Cabozantinib-s-malate may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth and also by blocking some of the enzymes needed for cell growth.

Fallopian Tube Clear Cell AdenocarcinomaOvarian Clear Cell AdenocarcinomaRecurrent Fallopian Tube Carcinoma+2 more

National Cancer Institute (NCI)13 participantsStarted Apr 2015

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +407 more locations

Testing the Influence of Different Sugary Drink Warning Label Designs

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Find Trials by Condition in Philadelphia

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

DIBH Proton Planning

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

VITROS Immunodiagnostic Products NT-proBNP II

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Defining the Optimal Location to Place an Adductor Canal Block

Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer

Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event